IP Library Granted Patent US 10,626,398
Granted Patent B2
US 10,626,398 · App. 16/253,180 · Granted Apr 21, 2020

Oligonucleotide compositions with enhanced efficiency

Inventors: Tod Woolf (Sudbury, MA); Margaret Taylor (Hopkinton, MA)
Assignee: LIFE TECHNOLOGIES CORPORATION
C12N15/1137A61K31/713C12N15/111C12N15/113C12N15/1135C12Y207/11022C12Y301/03048C12N2310/11C12N2310/111C12N2310/14C12N2310/315C12N2320/11C12N2320/30C12N2320/31C12N2320/50C12N2330/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,626,398
App. No.
16/253,180
Granted
Apr 21, 2020
Kind
B2
Abstract

The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.

Claims (37)

1. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three or more different double-stranded oligonucleotides in equimolar concentrations,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 15 and 40 nucleomonomers in length;

wherein the combination is capable of RNA interference (RNAi).

2. The composition of claim 1 wherein each strand is between 20 and 30 nucleomonomers in length.

3. The composition of claim 1 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

4. The composition of claim 1 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

5. The composition of claim 1 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

6. The composition of claim 1 , wherein the target gene is a mammalian gene.

7. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of two different double-stranded oligonucleotides in equimolar concentrations,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 15 and 40 nucleomonomers in length,

wherein the combination is capable of RNA interference (RNAi).

8. The composition of claim 7 wherein each strand is between 20 and 30 nucleomonomers in length.

9. The composition of claim 7 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

10. The composition of claim 7 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

11. The composition of claim 7 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

12. The composition of claim 7 , wherein the target gene is a mammalian gene.

13. A composition comprising a combination of double-stranded oligonucleotides, the combination consisting of three, four, five, six, seven or eight different double-stranded oligonucleotides in equimolar concentration,

wherein each double-stranded oligonucleotide is targeted to a different sequence within a single target gene,

each double-stranded oligonucleotide consists of two separate strands,

each strand is between 15 and 40 nucleomonomers in length,

wherein the combination is capable of RNA interference (RNAi).

14. The composition of claim 13 wherein each strand is between 20 and 30 nucleomonomers in length.

15. The composition of claim 13 wherein at least one of the oligonucleotides comprises at least one modified sugar moiety or at least one modified internucleoside linkage.

16. The composition of claim 13 wherein each double-stranded oligonucleotide comprises a nucleotide sequence that is at least 90% identical to a portion of the target gene.

17. The composition of claim 13 wherein at least one of the double-stranded oligonucleotides is covalently linked to an agent to facilitate cellular uptake.

18. The composition of claim 13 wherein the combination of double-stranded oligonucleotides consists of three or four different double-stranded oligonucleotides in equimolar concentration.

19. The composition of claim 18 wherein the combination of double-stranded oligonucleotides consists of four different double-stranded oligonucleotides in equimolar concentration.

20. A method of inhibiting protein synthesis in a cell comprising

contacting the cell with the composition of claim 1 thereby inhibiting the synthesis of a target protein.

21. A method of inhibiting protein synthesis in a cell comprising

contacting the cell with the composition of claim 7 thereby inhibiting the synthesis of a target protein.

22. A method of inhibiting protein synthesis in a cell comprising

contacting the cell with the composition of claim 13 thereby inhibiting the synthesis of a target protein.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2020
From: WOOLF, TOD; TAYLOR, MARGARET
To: SEQUITUR, INC.
Reel/Frame 051727/0335 →
MERGER Recorded Feb 5, 2020
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 051727/0649 →
MERGER Recorded Feb 5, 2020
From: SEQUITUR, INC.
To: INVITROGEN CORPORATION
Reel/Frame 051830/0712 →